biotech / news / / ThePrint
Regeneron’s co-founder and CEO, Leonard Schleifer, said in a statement that the American taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation.
Regeneron's Otarmeni is the first therapy enabling deaf children to hear without implants.
KEY POINTS
- Otarmeni delivers a working otoferlin gene directly to the cochlea, avoiding traditional surgery.
- Other companies, including Eli Lilly and Skylark Bio, as well as China and France, are developing similar gene therapies.
- Scientists are starting to target the more complex GJB2 gene mutation responsible for 20% of congenital hearing loss.
COMPANIES
Summarized by Newsio from ThePrint. How we summarize →